R

Roche

Global pharmaceuticals and diagnostics company

ITOT System Release Associate Manager

Full-Time
No salary listed
Expert
Bachelor's
Shanghai, China
In Person
IT OperationsIT Project Management, Enterprise Applications

About the job

Requirements
  • A bachelor's degree in Computer Science, Electrical Engineering – Automation, Applied Computer Science, Business Informatics, Engineering, or a comparable degree.
  • At least 10 years of experience in production- or quality-related processes involving ERP and ITOT system development, service management methodology (ITIL), and data processing.
  • Very good system knowledge of SAP S/4 (ERP), EWM, and the ITOT system landscape.
  • Very good standard software knowledge.
  • Very good knowledge of pharmaceutical production and quality processes.
  • Very good English language skills.
  • Proven project management skills.
  • Ability and willingness to proactively identify challenges and solutions, learn new things, share knowledge, and develop best practices.
  • Service delivery expertise with an agile mindset.
  • Curiosity to explore new technologies and learn new concepts to solve problems sustainably and effectively.
  • Customer service experience with analytical and critical thinking skills.
  • Ability to communicate clearly and precisely with non-technical stakeholders.
  • High flexibility.
Responsibilities
  • Develop a cross-system strategy for implementing product increments and release updates for critical systems in the ITOT system landscape.
  • Monitor activities throughout the product increment cycle and ensure defined features and optimizations are delivered.
  • Define and monitor key performance indicators, including delivery percentage, risks, and lead time, and derive measures for continuous improvement.
  • Lead site-specific planning and coordinate execution during product increment and release implementation.
  • Conduct site-specific technical impact assessments and ensure production and packaging remain possible during downtime.
  • Ensure, with the ITOT leadership team, that expert teams working on product increments have adequate resources, including budgets and time, and are supported.
  • Ensure dependencies and risks are identified during planning and that appropriate countermeasures are implemented.
  • Align priorities, change impacts, and downtime with stakeholders, including technical SPS of ITOT, Planning, and the Business Owner.
  • Ensure compliance with local and global regulations together with QA functions.
  • Act as the single point of contact throughout the product increment cycle and the first point of contact for escalations.
  • Coordinate communications with stakeholders throughout the product increment cycle and ensure delivered results meet expectations, applying a business mindset focused on safety and quality and an agile approach to fast, stable, and reliable service delivery.
  • Act as the single point of contact for the BPE community.
  • Define and prioritize new requirements and functional changes with the BPE community and in coordination with the SPS community.
  • Maintain and update the Product Backlog, ensuring requirements from global and local IT products and the local ITOT system landscape are considered.
  • Communicate features and requirements affecting S/4 to the ARTs and ensure their inclusion in corresponding Product Backlogs.
  • Divide local requirements and analysis of impacts on the local system landscape into manageable work packages and provide corresponding feedback to the S/4 ARTs.
  • Align product increments with the overall product roadmap of the local ITOT system landscape.
  • Ensure delivery deadlines are met and product increments are delivered and released with high quality.
  • Plan according to customer priorities and needs with the aim of minimizing downtime.
  • Provide on-site and remote application support for ASPIRE systems, liaising between end users and business single points of contact.
  • Proactively troubleshoot system interfaces, including MES, EWM, and S/4, and escalate and follow up on complex operational issues with global teams.
  • Act as an ITOT subject matter expert in inspection, audit, and quality-event activities.
  • Identify, mitigate, or escalate risks that may affect successful product increment delivery.
  • Proactively manage problems during the product increment cycle to resolve them quickly and avoid delays.
  • Develop workaround strategies and coordinate their implementation.
  • Escalate critical risks or problems to the globally responsible unit when they could affect delivery deadlines, generate additional workarounds, or impair site productivity.
  • Actively coordinate problem management during downtime, cutover, Return2Service, and hypercare with BSS, the Ops Agile Teams (ASPIRE), and ITOT Leads.
  • Lead retrospectives and post-product-increment reviews to identify improvements to planning and execution.
  • Encourage teams to apply agile best practices and improve speed and quality over time.
  • Promote continuous improvement initiatives to improve the efficiency and effectiveness of future product increments.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 22nd, 2026
Roche reaffirms outlook as Q3 sales rise 7% to $19.6B, but growth doubts linger

Roche reaffirmed its 2025 outlook on Thursday and beat third-quarter sales expectations, but questions about its long-term growth remain. Group sales rose 7% to 16.1 billion Swiss francs (about $19.6 billion), ahead of the 15.8 billion franc consensus estimate. Jefferies analyst Michael Leuchten said a new resource planning system boosted revenue, making the results "cosmetically ahead." Roche still expects group sales growth in the "mid single digit range" and did not raise guidance. Sales of allergy and asthma drug Xolair reached only 848 million francs, well below estimates. A copycat version launched in the US this month, and Ocrevus and Tecentriq face generic competition by 2030. Roche is counting on its breast cancer pill giredestrant, which awaits a US Food and Drug Administration decision by December 18, and on obesity drugs. It says the products could together reach $9 billion in peak annual sales.

CNBC
Oct 22nd, 2026
Roche CEO presses Germany on growth strategy as drugmaker pauses investment there

Roche chief executive officer Thomas Schinecker has challenged Germany over its growth strategy, saying pharmaceutical firms are "the industry they need to bet on." Schinecker discussed the company's third-quarter earnings and its recent expansion in China. He also outlined recent pharmaceutical developments at the business. He explained why Roche has paused investment in Germany.

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.